DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Condition: Breast Cancer
Sponsor: DualityBio Inc.
Full Title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
Study Treatment
Cohort 2m: HER2 targeting antibody drug conjugate DB-1303/BNT323 +/- pertuzumab
Eligibility/Info
Cohort 2m: HER2-positive (IHC3+ or IHC2+ and ISH+) metastatic breast cancer that has not been treated systemically in the advanced/metastatic setting.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
